OCTA Biomarker Search in Patients with nAMD: Influence of Retinal Fluid on Time-Dependent Biomarker Response.
Humans
Angiogenesis Inhibitors
/ therapeutic use
Vascular Endothelial Growth Factor A
/ therapeutic use
Visual Acuity
Wet Macular Degeneration
/ drug therapy
Retina
Choroidal Neovascularization
/ drug therapy
Biomarkers
Tomography, Optical Coherence
/ methods
Fluorescein Angiography
Intravitreal Injections
MNV
Retina
SSOCTA
biomarker
nAMD
Journal
Current eye research
ISSN: 1460-2202
Titre abrégé: Curr Eye Res
Pays: England
ID NLM: 8104312
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
medline:
16
5
2023
pubmed:
10
3
2023
entrez:
9
3
2023
Statut:
ppublish
Résumé
Previous studies have identified a link between optical coherence tomography (OCT)-derived and OCT angiography (OCTA)-based parameters in patients with neovascular AMD (nAMD); the latter may serve as direct biomarkers for macular neovascularization (MNV) activity. The aim of this study was to assess the individual influence of retinal thickness (RT) as well as intra- and sub-retinal fluid (IRF, SRF) presence on the treatment response over time as assessed by previously identified OCTA-derived MNV vascular parameters. During the first 3 months of anti-VEGF therapy patients were prospectively followed. RT, SRF and IRF were determined from SSOCT/A (PlexElite, Zeiss) images and using the semi-automated AngioTool software, vessel area (VA), total vessel length (TVL), total number of junctions (TNJ), junction density (JD), vessel density (VD) as well as MNV area were exported. IRF and SRF were identified manually on OCT volume scans .The associations between RT, IRF, and SRF and SSOCTA vascular parameters were analyzed using linear mixed models. 31 eyes of 31 patients with treatment-naïve and OCTA-positive nAMD MNV were included in this analysis. VA, TVL, TNJ, and MNV area show a statistically significant change over time in response to anti-VEGF treatment, even after correcting for the presence of SRF, IRF, or RT (all OCTA-based parameters VA, TVL, TNJ, and MNVarea show a strong response to anti-VEGF therapy over time, independent of the presence of IRF, SRF or RT. We conclude that the above listed OCTA parameters could contribute to our understanding of MNV biology and to guide individualized treatment in the future. The authors confirm that all ongoing and related trials are registered. ClinicalTrials.gov Number: NCT02521142.
Identifiants
pubmed: 36891909
doi: 10.1080/02713683.2023.2184318
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02521142']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM